We use cookies for a better user experience. Read our Privacy Policy

I Agree

Kidney Cancer Drugs Market

Kidney Cancer Drugs Market (Major Drugs: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib)) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Global Kidney Cancer Drugs Market: Overview

The global kidney cancer drugs market is projected to witness a steep growth during the tenure of 2014 to 2020. This growth of the market is attributed to the growth of growing number of patients suffering from kidney cancer. The rise in the number of patients is the major factor that propels the growth of global kidney cancer drugs market says a recent report by Transparency Market. The report also states that owing to unhealthy diets and various pollution substrates present in the atmosphere, shall increase the number of cancer across the globe.

A report by Transparency Market Research provides in-depth analysis of the dynamics of the global kidney cancer drugs market shall witness an exponential growth in coming years from 2014 to 2020. To provide actionable insights to the readers, the report enlightens facets such as challenges, opportunities, and trends that are prevalent in the global kidney cancer drugs market.

Owing to the outbreak of corona virus, the global kidney cancer drugs market is currently highly competitive. Moreover, since the dominance over the market is majorly of the emerging players which make the global kidney cancer drugs market a highly fragmented. In order to stay ahead of the curve, and cater to the growing demand for global kidney cancer drugs, the players are adopting various strategies.

The new players are resorting to strategies such as mergers and collaborations. These strategies help the players to accommodate resources that can help them have a sustainable future in the global kidney cancer drugs market.

On the other hand strategies such as research and development are also helping the players to gain a competitive edge over the rivals in the global kidney cancer drugs market tenure of 2014 to 2020.

Global Kidney Cancer Drugs Market: Trend and Drivers

Developing Health and Wellness Sector to Boost the Growth

The worldwide kidney cancer drugs market is probably going to extend at a consistent pace in the coming years. This is basically because of the elements, for example, rising geriatric populace, changes in way of life, and expanding utilization of dangerous items, for example, liquor. Aside from this, factors like simple accessibility of novel medications is boosting utilization of kidney cancer drugs. This is basically a direct result of the nearness of store network for sedate inventory. This is required to enlarge development in the worldwide kidney cancer drugs market. Also producer of the kidney cancer drugs are propelling on the web gateway for deals of medications. This is additionally expected to upgrade their stockpile and help the players to have a significant edge over their rival.

Global Kidney Cancer Drugs Market: Challenges

Availability of cutting edge medications, for example, immunotherapy and insusceptible oncologic is probably going to help appropriation rate. This is on the grounds that these novel medications are more powerful than focused treatments to explicit patient subpopulation. This is offering a superior treatment results than conventional medications accessible in the market. On the flipside, regardless of a few drivers the development in the worldwide kidney cancer drugs market is hampered attributable to significant expense of medication and exorbitant treatment methodology.

Global Kidney Cancer Drugs Market: Regional Analysis

North America is relied upon to ascend at a most noteworthy pace during the conjecture time frame. This is for the most part because of the expanding request of productive kidney malignant growth medicates in the district because of the expanding cases. Alongside this, nearness of created medicinal services foundation and better clinical repayment offices in the district are some different variables moving the worldwide kidney cancer drugs market.

Kidney Cancer Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Kidney Cancer Drugs Market
2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2013 and 2020 (Value %)
 
Chapter 3 Global Kidney Cancer Drugs Market Overview
3.1 Market Dynamics and Overview
3.2 Market Drivers
     3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth
     3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market
             3.2.2.1.1 Global Percentage Change in the World’s Population by Age: 2010-2050
     3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth
3.3 Market Restraints
     3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market
     3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth
3.4 Market Opportunities
     3.4.1 Focusing on Emerging Markets
3.5 Event Impact Analysis
3.6 Regulatory Framework
3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
 
Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs
4.1 Overview
     4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million)
4.2 Sutent (Sunitinib)
     4.2.1 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million)
4.3 Nexavar (Sorafenib)
     4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million)
4.4 Afinitor (Everolimus)
     4.4.1 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million)
4.5 Votrient (Pazopanib)
     4.5.1 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million)
4.6 Inlyta (Axitinib)
     4.6.1 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million)
4.7 Avastin (Bevacizumab)
     4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)
4.8 Torisel (Temsirolimus)
     4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million)
4.9 Proleukin (Aldesleukin)
     4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis
5.1 Overview
     5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million)
5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)
     5.2.1 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)
5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
     5.3.1 Global Keytruda Market Revenue, 2015 – 2020 (USD Million)
5.4 Cabozantinib (XL184) (Exelixis, Inc.)
     5.4.1 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million)
5.5 AGS-003 (Argus Therapeutics, Inc.)
     5.5.1 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million)
5.6 Dovitinib (TK1258) [Novartis AG]
     5.6.1 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)
 
Chapter 6 Global Kidney Cancer Drugs Market, by Geography
6.1 Overview
     6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
     6.2.1 North America Kidney Cancer Drugs Market Revenue, 2012–2020 (USD Million)
6.3 Europe
     6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
     6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
     6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 7 Recommendations
 
Chapter 8 Company Profiles
8.1 Bayer AG
     8.1.1 Company Overview
     8.1.2 Financial Overview
     8.1.3 Product Portfolio
     8.1.4 Business Strategy
     8.1.5 Recent Developments
8.2 F. Hoffmann-La Roche, Ltd.
     8.2.1 Company Overview
     8.2.2 Financial Overview
     8.2.3 Product Portfolio
     8.2.4 Business Strategy
     8.2.5 Recent Developments
8.3 GlaxoSmithKline, plc
     8.3.1 Company Overview
     8.3.2 Financial Overview
     8.3.3 Product Portfolio
     8.3.4 Business Strategy
     8.3.5 Recent Developments
8.4 Novartis AG
     8.4.1 Company Overview
     8.4.2 Financial Overview
     8.4.3 Product Portfolio
     8.4.4 Business Strategy
     8.4.5 Recent Developments
8.5 Pfizer, Inc.
     8.5.1 Company Overview
     8.5.2 Financial Overview
     8.5.3 Product Portfolio
     8.5.4 Business Strategy
     8.5.5 Recent Developments
List of Tables
 
TABLE 1 Market Snapshot: Global Kidney Cancer Market
TABLE 2 Stages of RCC, According to the U.S. TNM Classification
TABLE 3 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 – 2020 (USD Million)
TABLE 4 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 – 2020 (USD Million)
TABLE 5 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)

List of Figures

 

FIG. 1 Kidney Cancer Drugs: Market Segmentation

FIG. 2 Global Kidney Cancer Drugs Market, by Major Branded Drugs, 2013 (USD Million)

FIG. 3 Global Kidney Cancer Pipeline Drugs Market (USD Million)

FIG. 4 Comparative Analysis: Global Kidney Cancer Drugs Market, by Geography, 2013 and 2020 (Value %)

FIG. 5 Kidney Cancer Drugs Market, Drivers and Restraints

FIG. 6 Global Percentage Change in the World’s Population by Age: 2010 - 2050

FIG. 7 Major Developments in Kidney Cancer Drugs Market

FIG. 8 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography

FIG. 9 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)

FIG. 10 Global Sutent (Sunitinib) Market Revenue, 2012 – 2020 (USD Million)

FIG. 11 Global Nexavar (Sorafenib) Market Revenue, 2012 – 2020 (USD Million)

FIG. 12 Global Afinitor (Everolimus) Market Revenue, 2012 – 2020 (USD Million)

FIG. 13 Global Votrient (Pazopanib) Market Revenue, 2012 – 2020 (USD Million)

FIG. 14 Global Inlyta (Axitinib) Market Revenue, 2012 – 2020 (USD Million)

FIG. 15 Global Avastin (Bevacizumab) Market Revenue, 2012 – 2020 (USD Million)

FIG. 16 Global Torisel (Temsirolimus) Market Revenue, 2012 – 2020 (USD Million)

FIG. 17 Global Proleukin (Aldesleukin) Market Revenue, 2012 – 2020 (USD Million)

FIG. 18 Global Opdivo Market Revenue, 2015 – 2020 (USD Million)

FIG. 19 Global Keytruda Market Revenue, 2015 – 2020 (USD Million)

FIG. 20 Global Cabozantinib Market Revenue, 2017 – 2020 (USD Million)

FIG. 21 Global AGS-003 Market Revenue, 2017 – 2020 (USD Million)

FIG. 22 Global Dovitinib Market Revenue, 2018 – 2020 (USD Million)

FIG. 23 North America Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)

FIG. 24 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)

FIG. 25 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)

FIG. 26 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)

FIG. 27 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 28 F. Hoffmann-La Roche, Ltd.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 29 GlaxoSmithKline, plc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 30 Annual Revenue: Novartis AG 2011 – 2013 (USD Million)

FIG. 31 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

325

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved